These are some of
the top analyst upgrades, downgrades,
and initiations seen
from Wall Street brokerage
and research firms
today.If
you
are
looking
to
day
trade,
you
might
want
to
check
out
the
following
stocks.
I
usually
throw
these
on
my
watch
list
and
monitor
with
resistance
&
support
levels.You
can
also
check
previous
stocks to
buy
reports- Right Here.
Mizuho Securities upgraded Progress Software (NASDAQ: PRGS) from Neutral to Underperform with a price target of $14.50 (from $21.00).Shares of Progress Software closed at $18.52 yesterday, with a 52 week range of $17.01-$24.76.
Jefferies upgraded Questcor Pharmaceuticals (NASDAQ: QCOR) from Hold to Buy with a price target of $28.00 (from $24.00), citing limited downside and improved visibility.
"We are upgrading QCOR to Buy from Hold given limited downside and improved visibility," analyst Biren Amin said. "We believe current valuation implies loss of MS and NS payer coverage. Our channel-checks with payers at AMCP suggest NS may be less at risk on lower Rx with improved cost-effectiveness via pot'l efficacybased measure and insurer rebates. Our new $28 PT assumes loss of MS sales, moderating NS growth, insurer rebates and a legal reserve."
Shares of Questcor Pharmaceuticals closed at $20.29 yesterday, with a 52 week range of $17.25-$58.91.
Credit Suisse downgraded Baidu (NASDAQ: BIDU) from Neutral to Underperform with an $83 price target.Shares of Baidu closed at $114.29 yesterday, with a 52 week range of $99.71-$154.15.
BofA/Merrill Lynch downgraded Netflix (NASDAQ: NFLX) two-notches from Buy to Underperform with a price target of $72.00 following the 31% run-up in the last few weeks.
The firm said bears have plenty to sink their teeth into including increasing domestic and international competition.
Mizuho Securities upgraded Progress Software (NASDAQ: PRGS) from Neutral to Underperform with a price target of $14.50 (from $21.00).Shares of Progress Software closed at $18.52 yesterday, with a 52 week range of $17.01-$24.76.
Jefferies upgraded Questcor Pharmaceuticals (NASDAQ: QCOR) from Hold to Buy with a price target of $28.00 (from $24.00), citing limited downside and improved visibility.
"We are upgrading QCOR to Buy from Hold given limited downside and improved visibility," analyst Biren Amin said. "We believe current valuation implies loss of MS and NS payer coverage. Our channel-checks with payers at AMCP suggest NS may be less at risk on lower Rx with improved cost-effectiveness via pot'l efficacybased measure and insurer rebates. Our new $28 PT assumes loss of MS sales, moderating NS growth, insurer rebates and a legal reserve."
Shares of Questcor Pharmaceuticals closed at $20.29 yesterday, with a 52 week range of $17.25-$58.91.
Credit Suisse downgraded Baidu (NASDAQ: BIDU) from Neutral to Underperform with an $83 price target.Shares of Baidu closed at $114.29 yesterday, with a 52 week range of $99.71-$154.15.
BofA/Merrill Lynch downgraded Netflix (NASDAQ: NFLX) two-notches from Buy to Underperform with a price target of $72.00 following the 31% run-up in the last few weeks.
The firm said bears have plenty to sink their teeth into including increasing domestic and international competition.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com
